TNF and inflammatory bowel disease: Furthermore, a consistent result has also been observed in our meta-cohort, lower D. scores in IBD patients were significantly associated with better clinical outcomes that the majority of patients responded to golimumab treatment and higher anti-TNF-alpha immunotherapies benefits (Figure 5E).